Sample Collection Completion for Pivotal US Clinical Trial
Filed with ASX · · 3 pages · English
Summary by 6ix AI
CLEO Diagnostics Ltd has announced the completion of sample collection for its pivotal U.S. clinical trial, marking a significant milestone in its development process for a Pre-Surgical Ovarian Cancer Test. The trial successfully enrolled a substantial number of participants, with blood samples collected from eligible patients, which will support the company's FDA submission. CLEO is also finalizing a manufacturing agreement for test kit production, which is a crucial step towards clinical testing.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Earlier from CLEO Diagnostics
- CLEO Optimises Biomarker Panel Ahead of FDA Submission
- Appendix 4D and Half Yearly Accounts
- CLEO Confirms Next-Gen Platform for Ovarian Cancer Test
- Quarterly activities and cashflow report
- CLEO Raises $5m to Support U.S. Market Launch
Later from CLEO Diagnostics
- CLEO Commences Kit Manufacturing Ahead of FDA Submission
- CLEO Establishes U.S. Reimbursement Pathway
- CLEO Enters Analytical Validation Phase
- Appendix 4E and 2026 Annual Report
- CLEO Receives First Batch of Commercial Test Kits
Follow CLEO Diagnostics into a list and get an email when it puts out news.
Follow CLEO Diagnostics